Pneumococcal Vaccine Market by Vaccine Type (Conjugate Vaccine, Polysaccharide Vaccine), Age Group (Adult, Children, Geriatric), Distribution Channel, End User - Global Forecast 2025-2032
Description
The Pneumococcal Vaccine Market was valued at USD 11.56 billion in 2024 and is projected to grow to USD 12.49 billion in 2025, with a CAGR of 8.16%, reaching USD 21.67 billion by 2032.
A concise orientation to the pneumococcal vaccine environment that situates scientific advances, policy drivers, and delivery realities to guide strategic focus
The pneumococcal vaccine landscape sits at a critical inflection point where scientific innovation, shifting immunization policies, and evolving delivery models intersect. This report opens with a clear-eyed orientation to the current environment, setting the stage for a focused examination of how vaccine modalities, demographic demand patterns, and distribution mechanisms are reshaping stakeholder priorities. Readers will find a compact narrative that frames recent developments in vaccine design alongside persistent public health challenges, highlighting the strategic implications for manufacturers, providers, payers, and policymakers.
Transitioning from background to context, the introduction synthesizes the most relevant drivers that define present-day strategic choices. It situates durable themes-such as the increasing prominence of conjugate formulations and the emphasis on life-course vaccination-within the operational realities of supply chain resilience and regulatory scrutiny. By clarifying these linkages early, the report primes decision-makers to interpret subsequent analysis through a lens that values clinical efficacy, adoption pathways, and system-level feasibility. The introduction ultimately orients readers to the core questions the report answers: how segment-specific demand and distribution patterns interact with technological and policy shifts to determine competitive positioning and programmatic success.
How innovations in vaccine design, life-course immunization policy, and evolving distribution paradigms are reshaping competitive dynamics and adoption pathways
The landscape for pneumococcal vaccination is undergoing transformative shifts driven by converging forces in immunology, regulatory frameworks, and healthcare delivery. Advances in conjugate vaccine design have extended serotype coverage and improved immunogenicity profiles, prompting regulators and immunization committees to re-evaluate schedules and recommendations. At the same time, public health priorities have broadened from pediatric programs to a life-course approach that integrates adult and geriatric vaccination into chronic disease prevention strategies. These shifts are reinforced by growing evidence on long-term herd effects and by heightened expectations for vaccines that balance broad protection with favorable safety and tolerability.
Concurrently, commercial dynamics are evolving as manufacturers innovate around dose-sparing formulations, thermostability, and platform technologies that can accelerate manufacturing scale-up. Distribution models are adapting: offline channels remain critical for clinic and hospital-based immunization, while online platforms and digital appointment systems increasingly facilitate access and adherence, particularly in urban and technologically enabled populations. Health systems are also prioritizing integration of vaccination into primary care workflows and ambulatory settings to reduce missed opportunities. Together, these changes are catalyzing new competitive behaviors, from strategic alliances to targeted market entry plans, and are shaping stakeholder expectations about product characteristics, availability, and lifecycle management.
Operational and procurement adaptations responding to tariff-related trade adjustments that influence vaccine sourcing, manufacturing footprint, and supply continuity
Recent trade policy adjustments and tariff measures affecting healthcare goods have created a nuanced operating environment for vaccines distributed into and out of the United States in 2025. These changes have influenced procurement strategies, cost structures, and the calculus for local manufacturing versus importation. Manufacturers and buyers are re-evaluating supply chain footprints to mitigate exposure to tariff volatility while maintaining supply continuity for routine immunization programs and targeted adult vaccination campaigns. Consequently, there is heightened scrutiny of end-to-end logistics, from raw material sourcing to finished-goods distribution, and an emphasis on contractual flexibility to absorb policy shifts.
In response, stakeholders have increasingly prioritized supply chain redundancy and nearshoring initiatives that reduce dependency on cross-border shipments subject to tariff fluctuations. Health systems and procurement agencies are negotiating contract terms that incorporate contingency clauses and tiered pricing arrangements. In parallel, manufacturers are accelerating investments in regional manufacturing capabilities and transfer-of-technology programs to maintain market access under new trade conditions. These operational responses aim to preserve immunization uptake by ensuring predictable product availability and by managing incremental cost pressures through process efficiencies and targeted cost sharing with payers and procurers.
Actionable segmentation insights linking vaccine modality, lifecycle age priorities, distribution channels, and end-user behaviors to optimize product positioning and delivery
A granular understanding of market segments clarifies where demand drivers, clinical priorities, and distribution preferences diverge, enabling tailored product and go-to-market strategies. Segmentation by vaccine type highlights the distinct trajectories of conjugate and polysaccharide platforms; conjugate options, which are further differentiated across PCV13, PCV15, and PCV20 formulations, are increasingly prioritized for their immunologic advantages and integration into routine schedules, whereas polysaccharide vaccines continue to play a role in targeted adult and catch-up use. Age-group segmentation separates priorities by lifecycle needs: pediatric programs emphasize early childhood schedules and programmatic coverage, adult vaccination strategies focus on chronic disease cohorts and occupational risk groups, and geriatric approaches center on immunosenescence and comorbidity-driven protection requirements.
Distribution channel segmentation reveals divergent adoption patterns between offline and online pathways; offline channels, encompassing clinics, hospitals, immunization centers, and ambulatory care settings, remain fundamental for routine population coverage and mass campaigns, while online mechanisms support appointment management, reminder systems, and direct-to-consumer education that can improve adherence. End-user segmentation further refines tactical decisions: ambulatory care centers and clinics are vital for routine and opportunistic vaccination during primary care visits, hospitals serve as critical touchpoints for high-risk and inpatient populations, and immunization centers drive community-based outreach and targeted public health initiatives. Synthesizing these segment dimensions allows manufacturers and program planners to align product attributes, messaging, and distribution investments to the specific operational and clinical realities of each cohort and channel.
Regional strategic priorities and delivery realities across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access, adoption, and program execution
Regional dynamics shape both strategic priorities and operational execution, with each geography presenting unique clinical, regulatory, and delivery challenges. In the Americas, immunization programs benefit from established pediatric schedules and increasing focus on adult vaccination integration; these markets exhibit advanced procurement mechanisms and growing interest in lifecycle vaccination frameworks. Regulatory pathways and reimbursement environments in the region support accelerated adoption of novel conjugate formulations when clinical advantages are clearly demonstrated, and public-private collaboration is commonly used to expand access.
In Europe, Middle East & Africa, heterogeneous health system capacities and variable funding models create a mosaic of opportunities and constraints. High-income European markets emphasize cost-effectiveness and comparative performance data to guide formulary decisions, while many countries in the Middle East & Africa rely on donor programs, tiered pricing, and supply partnerships to expand coverage. Capacity constraints in some settings highlight the importance of thermostable formulations and simplified dosing schedules to support programmatic deliverability. In the Asia-Pacific region, demographic diversity and rapidly modernizing healthcare infrastructures drive differentiated demand: urban centers are rapidly adopting digital distribution and private-sector vaccination services, whereas rural and resource-limited areas require robust cold-chain solutions and community-based delivery models. Across regions, alignment of clinical evidence, regulatory engagement, and tailored distribution strategies is essential to achieving sustained programmatic impact.
Industry competitive behaviors centered on platform innovation, manufacturing scale, and strategic partnerships to secure procurement pathways and programmatic uptake
Competitive dynamics among manufacturers and technology providers are shaped by a combination of portfolio breadth, manufacturing capacity, regulatory track record, and strategic partnerships. Leading organizations differentiate through investments in conjugate platforms that expand serotype coverage and by pursuing manufacturing innovations that improve yield, reduce cost of goods, and enhance thermostability. Simultaneously, a cohort of smaller biotech firms and contract manufacturing organizations contributes to the ecosystem by advancing novel platform technologies, offering fill-finish capacity, and enabling rapid scale-up under collaborative agreements.
Companies are also focusing on strategic alliances with public and private payers, as well as with regional distribution partners, to secure procurement pathways and to support program rollouts. Licensing and co-development agreements are frequently used to accelerate market entry into regions where local regulatory and distribution expertise is essential. From a commercial perspective, firms are refining value propositions to emphasize long-term clinical benefits, potential reductions in healthcare utilization, and contributions to antimicrobial resistance mitigation through disease prevention. Taken together, these industry behaviors reflect a shift toward integrated value-based engagement that aligns clinical evidence generation with pragmatic implementation and supply continuity.
Practical strategic moves for manufacturers and health systems to align clinical differentiation, supply resilience, and integrated distribution to accelerate adoption and access
Industry leaders should adopt a multi-faceted strategy that aligns scientific differentiation with pragmatic delivery capabilities and payer engagement. First, prioritize development and clinical programs that demonstrate meaningful clinical advantages in target age cohorts, with an emphasis on endpoints that resonate with payers and public health agencies, such as reductions in severe disease and hospitalization. Second, invest in supply chain resilience through regional manufacturing partnerships, technology transfers, and redundancy in critical inputs to protect against trade and logistic disruptions.
Third, build distribution strategies that integrate offline clinical relationships with digital channels to enhance access and adherence; this includes supporting clinic workflows, enabling appointment systems, and collaborating with immunization centers for community outreach. Fourth, engage early and transparently with regulators and HTA bodies to align evidence generation plans with reimbursement expectations, prioritizing real-world evidence collection and health economic models that reflect local care pathways. Fifth, pursue targeted collaborations with health systems and non-traditional partners to expand adult and geriatric vaccination programs, focusing on chronic disease clinics and ambulatory care touchpoints. Implementing these actions in concert will strengthen market access, improve uptake across age cohorts, and enhance the resilience of program delivery.
A transparent, evidence-driven research approach combining expert interviews, literature synthesis, segmentation analysis, and scenario validation to ensure actionable insights
This research employs a structured methodology that combines qualitative and quantitative evidence-gathering techniques to ensure robust, actionable insights. Primary data collection included structured interviews with clinical experts, procurement leaders, and supply-chain practitioners to capture decision-making criteria and operational constraints. Secondary research encompassed a comprehensive review of peer-reviewed clinical literature, regulatory statements, and public health guidance to synthesize current scientific consensus and policy direction. Data triangulation was used to reconcile findings across sources and to validate directional trends.
Analytical methods included segmentation analysis to examine how product attributes interact with age cohorts, distribution channels, and end-user needs. Scenario-based assessments were conducted to evaluate implications of supply chain disruptions and policy changes on procurement strategies. Findings were subjected to expert validation workshops to test assumptions and to refine practical recommendations. Throughout, emphasis was placed on transparency of sources and on documenting limitations where primary data were sparse, ensuring that conclusions remain evidence-informed and practically oriented for decision-makers seeking to apply insights to strategy and operations.
Concluding synthesis that connects clinical innovation, supply and delivery alignment, and payer engagement to enable sustained programmatic success and public health impact
The conclusion synthesizes the report’s principal lessons and reinforces the imperative for integrated approaches that connect scientific innovation with delivery and policy engagement. Advances in conjugate vaccine technology and evolving life-course immunization strategies offer clear clinical and public health opportunities, yet translating those advances into sustained programmatic impact requires deliberate alignment of manufacturing capacity, regulatory strategy, and distribution design. Stakeholders who proactively address supply chain resilience, prioritize evidence that matters to payers, and tailor distribution to the realities of age-specific demand will be best positioned to achieve durable uptake and health outcomes.
Ultimately, success in this environment depends on coordinated action: developers must pair clinical differentiation with implementation-friendly product features; health systems must integrate vaccination into routine care pathways across ambulatory, clinic, hospital, and immunization center settings; and commercial teams must build partnerships that reduce friction in procurement and delivery. When these elements are aligned, pneumococcal vaccination programs can realize greater population protection and more efficient use of healthcare resources. The report closes with practical recommendations designed to help leaders convert insight into scalable action.
Please Note: PDF & Excel + Online Access - 1 Year
A concise orientation to the pneumococcal vaccine environment that situates scientific advances, policy drivers, and delivery realities to guide strategic focus
The pneumococcal vaccine landscape sits at a critical inflection point where scientific innovation, shifting immunization policies, and evolving delivery models intersect. This report opens with a clear-eyed orientation to the current environment, setting the stage for a focused examination of how vaccine modalities, demographic demand patterns, and distribution mechanisms are reshaping stakeholder priorities. Readers will find a compact narrative that frames recent developments in vaccine design alongside persistent public health challenges, highlighting the strategic implications for manufacturers, providers, payers, and policymakers.
Transitioning from background to context, the introduction synthesizes the most relevant drivers that define present-day strategic choices. It situates durable themes-such as the increasing prominence of conjugate formulations and the emphasis on life-course vaccination-within the operational realities of supply chain resilience and regulatory scrutiny. By clarifying these linkages early, the report primes decision-makers to interpret subsequent analysis through a lens that values clinical efficacy, adoption pathways, and system-level feasibility. The introduction ultimately orients readers to the core questions the report answers: how segment-specific demand and distribution patterns interact with technological and policy shifts to determine competitive positioning and programmatic success.
How innovations in vaccine design, life-course immunization policy, and evolving distribution paradigms are reshaping competitive dynamics and adoption pathways
The landscape for pneumococcal vaccination is undergoing transformative shifts driven by converging forces in immunology, regulatory frameworks, and healthcare delivery. Advances in conjugate vaccine design have extended serotype coverage and improved immunogenicity profiles, prompting regulators and immunization committees to re-evaluate schedules and recommendations. At the same time, public health priorities have broadened from pediatric programs to a life-course approach that integrates adult and geriatric vaccination into chronic disease prevention strategies. These shifts are reinforced by growing evidence on long-term herd effects and by heightened expectations for vaccines that balance broad protection with favorable safety and tolerability.
Concurrently, commercial dynamics are evolving as manufacturers innovate around dose-sparing formulations, thermostability, and platform technologies that can accelerate manufacturing scale-up. Distribution models are adapting: offline channels remain critical for clinic and hospital-based immunization, while online platforms and digital appointment systems increasingly facilitate access and adherence, particularly in urban and technologically enabled populations. Health systems are also prioritizing integration of vaccination into primary care workflows and ambulatory settings to reduce missed opportunities. Together, these changes are catalyzing new competitive behaviors, from strategic alliances to targeted market entry plans, and are shaping stakeholder expectations about product characteristics, availability, and lifecycle management.
Operational and procurement adaptations responding to tariff-related trade adjustments that influence vaccine sourcing, manufacturing footprint, and supply continuity
Recent trade policy adjustments and tariff measures affecting healthcare goods have created a nuanced operating environment for vaccines distributed into and out of the United States in 2025. These changes have influenced procurement strategies, cost structures, and the calculus for local manufacturing versus importation. Manufacturers and buyers are re-evaluating supply chain footprints to mitigate exposure to tariff volatility while maintaining supply continuity for routine immunization programs and targeted adult vaccination campaigns. Consequently, there is heightened scrutiny of end-to-end logistics, from raw material sourcing to finished-goods distribution, and an emphasis on contractual flexibility to absorb policy shifts.
In response, stakeholders have increasingly prioritized supply chain redundancy and nearshoring initiatives that reduce dependency on cross-border shipments subject to tariff fluctuations. Health systems and procurement agencies are negotiating contract terms that incorporate contingency clauses and tiered pricing arrangements. In parallel, manufacturers are accelerating investments in regional manufacturing capabilities and transfer-of-technology programs to maintain market access under new trade conditions. These operational responses aim to preserve immunization uptake by ensuring predictable product availability and by managing incremental cost pressures through process efficiencies and targeted cost sharing with payers and procurers.
Actionable segmentation insights linking vaccine modality, lifecycle age priorities, distribution channels, and end-user behaviors to optimize product positioning and delivery
A granular understanding of market segments clarifies where demand drivers, clinical priorities, and distribution preferences diverge, enabling tailored product and go-to-market strategies. Segmentation by vaccine type highlights the distinct trajectories of conjugate and polysaccharide platforms; conjugate options, which are further differentiated across PCV13, PCV15, and PCV20 formulations, are increasingly prioritized for their immunologic advantages and integration into routine schedules, whereas polysaccharide vaccines continue to play a role in targeted adult and catch-up use. Age-group segmentation separates priorities by lifecycle needs: pediatric programs emphasize early childhood schedules and programmatic coverage, adult vaccination strategies focus on chronic disease cohorts and occupational risk groups, and geriatric approaches center on immunosenescence and comorbidity-driven protection requirements.
Distribution channel segmentation reveals divergent adoption patterns between offline and online pathways; offline channels, encompassing clinics, hospitals, immunization centers, and ambulatory care settings, remain fundamental for routine population coverage and mass campaigns, while online mechanisms support appointment management, reminder systems, and direct-to-consumer education that can improve adherence. End-user segmentation further refines tactical decisions: ambulatory care centers and clinics are vital for routine and opportunistic vaccination during primary care visits, hospitals serve as critical touchpoints for high-risk and inpatient populations, and immunization centers drive community-based outreach and targeted public health initiatives. Synthesizing these segment dimensions allows manufacturers and program planners to align product attributes, messaging, and distribution investments to the specific operational and clinical realities of each cohort and channel.
Regional strategic priorities and delivery realities across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access, adoption, and program execution
Regional dynamics shape both strategic priorities and operational execution, with each geography presenting unique clinical, regulatory, and delivery challenges. In the Americas, immunization programs benefit from established pediatric schedules and increasing focus on adult vaccination integration; these markets exhibit advanced procurement mechanisms and growing interest in lifecycle vaccination frameworks. Regulatory pathways and reimbursement environments in the region support accelerated adoption of novel conjugate formulations when clinical advantages are clearly demonstrated, and public-private collaboration is commonly used to expand access.
In Europe, Middle East & Africa, heterogeneous health system capacities and variable funding models create a mosaic of opportunities and constraints. High-income European markets emphasize cost-effectiveness and comparative performance data to guide formulary decisions, while many countries in the Middle East & Africa rely on donor programs, tiered pricing, and supply partnerships to expand coverage. Capacity constraints in some settings highlight the importance of thermostable formulations and simplified dosing schedules to support programmatic deliverability. In the Asia-Pacific region, demographic diversity and rapidly modernizing healthcare infrastructures drive differentiated demand: urban centers are rapidly adopting digital distribution and private-sector vaccination services, whereas rural and resource-limited areas require robust cold-chain solutions and community-based delivery models. Across regions, alignment of clinical evidence, regulatory engagement, and tailored distribution strategies is essential to achieving sustained programmatic impact.
Industry competitive behaviors centered on platform innovation, manufacturing scale, and strategic partnerships to secure procurement pathways and programmatic uptake
Competitive dynamics among manufacturers and technology providers are shaped by a combination of portfolio breadth, manufacturing capacity, regulatory track record, and strategic partnerships. Leading organizations differentiate through investments in conjugate platforms that expand serotype coverage and by pursuing manufacturing innovations that improve yield, reduce cost of goods, and enhance thermostability. Simultaneously, a cohort of smaller biotech firms and contract manufacturing organizations contributes to the ecosystem by advancing novel platform technologies, offering fill-finish capacity, and enabling rapid scale-up under collaborative agreements.
Companies are also focusing on strategic alliances with public and private payers, as well as with regional distribution partners, to secure procurement pathways and to support program rollouts. Licensing and co-development agreements are frequently used to accelerate market entry into regions where local regulatory and distribution expertise is essential. From a commercial perspective, firms are refining value propositions to emphasize long-term clinical benefits, potential reductions in healthcare utilization, and contributions to antimicrobial resistance mitigation through disease prevention. Taken together, these industry behaviors reflect a shift toward integrated value-based engagement that aligns clinical evidence generation with pragmatic implementation and supply continuity.
Practical strategic moves for manufacturers and health systems to align clinical differentiation, supply resilience, and integrated distribution to accelerate adoption and access
Industry leaders should adopt a multi-faceted strategy that aligns scientific differentiation with pragmatic delivery capabilities and payer engagement. First, prioritize development and clinical programs that demonstrate meaningful clinical advantages in target age cohorts, with an emphasis on endpoints that resonate with payers and public health agencies, such as reductions in severe disease and hospitalization. Second, invest in supply chain resilience through regional manufacturing partnerships, technology transfers, and redundancy in critical inputs to protect against trade and logistic disruptions.
Third, build distribution strategies that integrate offline clinical relationships with digital channels to enhance access and adherence; this includes supporting clinic workflows, enabling appointment systems, and collaborating with immunization centers for community outreach. Fourth, engage early and transparently with regulators and HTA bodies to align evidence generation plans with reimbursement expectations, prioritizing real-world evidence collection and health economic models that reflect local care pathways. Fifth, pursue targeted collaborations with health systems and non-traditional partners to expand adult and geriatric vaccination programs, focusing on chronic disease clinics and ambulatory care touchpoints. Implementing these actions in concert will strengthen market access, improve uptake across age cohorts, and enhance the resilience of program delivery.
A transparent, evidence-driven research approach combining expert interviews, literature synthesis, segmentation analysis, and scenario validation to ensure actionable insights
This research employs a structured methodology that combines qualitative and quantitative evidence-gathering techniques to ensure robust, actionable insights. Primary data collection included structured interviews with clinical experts, procurement leaders, and supply-chain practitioners to capture decision-making criteria and operational constraints. Secondary research encompassed a comprehensive review of peer-reviewed clinical literature, regulatory statements, and public health guidance to synthesize current scientific consensus and policy direction. Data triangulation was used to reconcile findings across sources and to validate directional trends.
Analytical methods included segmentation analysis to examine how product attributes interact with age cohorts, distribution channels, and end-user needs. Scenario-based assessments were conducted to evaluate implications of supply chain disruptions and policy changes on procurement strategies. Findings were subjected to expert validation workshops to test assumptions and to refine practical recommendations. Throughout, emphasis was placed on transparency of sources and on documenting limitations where primary data were sparse, ensuring that conclusions remain evidence-informed and practically oriented for decision-makers seeking to apply insights to strategy and operations.
Concluding synthesis that connects clinical innovation, supply and delivery alignment, and payer engagement to enable sustained programmatic success and public health impact
The conclusion synthesizes the report’s principal lessons and reinforces the imperative for integrated approaches that connect scientific innovation with delivery and policy engagement. Advances in conjugate vaccine technology and evolving life-course immunization strategies offer clear clinical and public health opportunities, yet translating those advances into sustained programmatic impact requires deliberate alignment of manufacturing capacity, regulatory strategy, and distribution design. Stakeholders who proactively address supply chain resilience, prioritize evidence that matters to payers, and tailor distribution to the realities of age-specific demand will be best positioned to achieve durable uptake and health outcomes.
Ultimately, success in this environment depends on coordinated action: developers must pair clinical differentiation with implementation-friendly product features; health systems must integrate vaccination into routine care pathways across ambulatory, clinic, hospital, and immunization center settings; and commercial teams must build partnerships that reduce friction in procurement and delivery. When these elements are aligned, pneumococcal vaccination programs can realize greater population protection and more efficient use of healthcare resources. The report closes with practical recommendations designed to help leaders convert insight into scalable action.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
186 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rapid integration of novel 20-valent pneumococcal conjugate vaccine in national immunization programs
- 5.2. Expansion of public private partnerships to improve vaccine access in underserved regions
- 5.3. Growing investment in mRNA based pneumococcal vaccine platforms for faster development
- 5.4. Shifting epidemiology with emergence of non vaccine serotypes driving next generation formulations
- 5.5. Regulatory accelerated approval pathways facilitating faster market entry for novel pneumococcal vaccines
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Pneumococcal Vaccine Market, by Vaccine Type
- 8.1. Conjugate Vaccine
- 8.1.1. Pcv13
- 8.1.2. Pcv15
- 8.1.3. Pcv20
- 8.2. Polysaccharide Vaccine
- 9. Pneumococcal Vaccine Market, by Age Group
- 9.1. Adult
- 9.2. Children
- 9.3. Geriatric
- 10. Pneumococcal Vaccine Market, by Distribution Channel
- 10.1. Offline
- 10.2. Online
- 11. Pneumococcal Vaccine Market, by End User
- 11.1. Ambulatory Care Centers
- 11.2. Clinics
- 11.3. Hospitals
- 11.4. Immunization Centers
- 12. Pneumococcal Vaccine Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Pneumococcal Vaccine Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Pneumococcal Vaccine Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Abbott
- 15.3.2. Astellas Pharma Inc.
- 15.3.3. Beijing Minhai Biotechnology Co., Ltd.
- 15.3.4. Bharat Biotech International Ltd.
- 15.3.5. Biological E. Limited
- 15.3.6. BioNTech SE
- 15.3.7. GSK plc
- 15.3.8. Inventprise LLC
- 15.3.9. KM Biologics Co., Ltd.
- 15.3.10. LG Chem Ltd.
- 15.3.11. Merck & Co., Inc.
- 15.3.12. Novartis AG
- 15.3.13. Panacea Biotec Ltd.
- 15.3.14. Pfizer Inc.
- 15.3.15. Pnuvax Incorporated
- 15.3.16. Sanofi S.A.
- 15.3.17. Serum Institute of India Pvt. Ltd.
- 15.3.18. Shenzhen Kangtai Biological Products Co., Ltd.
- 15.3.19. SK Bioscience Co., Ltd.
- 15.3.20. Vaxcyte Inc.
- 15.3.21. Walvax Biotechnology Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
